Developing Trends in the Specialty Drug Pipeline

At the Academy of Managed Care Pharmacy's Managed Care & Specialty Pharmacy Annual Meeting, held April 23-26, in Boston, Massachusetts, an overflow capacity crowd gathered for one of the meeting’s yearly highlights­: Specialty Pharmaceuticals in Development. Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts, talked about the key trends in the specialty drug market, including cancer medications, new competition, and orphan drugs.

Six specialty classes are maturing, she said, including HIV, multiple sclerosis (MS), and drugs for psoriasis, and there is a $25 billion market opportunity through 2022 as 64 drugs come off patent protection.

Likewise, there is a similar opportunity in biosimiliars, as 71 patents lose protection through 2021, creating a $54.4 billion market. There are 10 biosimiliars pending approval this year, targeting treatments for anemia, breast cancer, neutropenia, rheumatoid arthritis (RA), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and psoriasis. But there are significant legal hurdles in the biosimiliar market, and the FDA is working on policies to open up competition. Eventually, it will lead to significant cost savings, she said.

Market share capture varies by drug, however.

“It just seems to be taking a bit a little bit longer than we would like,” Tharaldson said. In 5 years, there could be numerous biosimiliars to the immunosuppressant drug Humira—a $16 billion market, she noted.
 
Click to continue reading on The American Journal of Managed Care.




Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.
Individuals with HIV maintained similar rates of viral suppression after switching from a 3-drug regimen to the 2-drug regimen of dolutegravir plus lamivudine.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$